Summary of Conference Call for Anbiping Company Overview - **Company**: Anbiping - **Industry**: Medical diagnostics, specifically focusing on HPV screening, immunohistochemistry, and AI applications in pathology Key Points and Arguments Market Strategy and Performance - Anbiping's shift from direct sales to distribution has impacted factory prices, but sales volume increased in Q2 2025, with expectations of recovery in the second half of the year as the impact of centralized procurement (集采) ends in August [2][3] - The company has received 13 CE certifications for immunohistochemistry and liquid-based cytology, which are crucial for its international expansion strategy [2][5] - The HPV screening market penetration is high, with a growth rate of approximately 7% in Q1 2025, driven by national initiatives to eliminate cervical cancer by 2030 [2][6] Competitive Landscape - Major player Capbio holds over 30% market share, and the market share distribution remains stable post-centralized procurement, limiting new entrants due to price pressures [2][7] - Anbiping's AI cervical cytology product has been commercialized, with 296 scanners sold, capturing about 15% market share [2][8] Financial Performance - In Q1 2025, Anbiping's revenue declined by 28% due to a drop in factory prices from 45 RMB to 13 RMB as a result of centralized procurement [3] - The company anticipates a net profit margin of over 15% in the future, despite current challenges [4][27] Research and Development - Anbiping plans to invest 70 million RMB in R&D in 2025, focusing on immunohistochemistry and AI technologies [4][14] - The company aims to enhance its AI product quality and explore new business models, as current regulations prevent separate charging for AI services [9][16] Future Outlook - The immunohistochemistry market is growing at an annual rate of about 20%, with Anbiping targeting 1 billion RMB in revenue from this segment [2][10] - The company is prioritizing the promotion of its AI cervical cytology product due to its higher revenue potential compared to HPV testing [21] - Anbiping's overseas sales are expected to double in 2025, with a focus on Southeast Asia and Europe, avoiding highly competitive markets like the U.S. [22][23] Regulatory and Market Challenges - The company faces challenges from centralized procurement and channel adjustments but sees opportunities from competitors exiting the Chinese market [25][29] - The pathology industry is expected to grow, with potential price increases for diagnostic services due to policy support [20] Conclusion - Anbiping is navigating a challenging environment with strategic adjustments in sales, a focus on R&D, and leveraging market opportunities from competitor exits. The company is positioned for potential growth in the coming years, particularly in the AI and immunohistochemistry sectors [28][29]

Company Overview - Anbiping's closing price on July 11 was 29.62 yuan, up 3.82%, with a rolling PE ratio of 1238.65, marking a new low in 22 days, and a total market capitalization of 2.771 billion yuan [1] - The company operates in the medical device industry, focusing on tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] Financial Performance - For Q1 2025, Anbiping reported revenue of 72.5435 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.0645 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Industry Comparison - The average PE ratio for the medical device industry is 52.06, with a median of 37.22, placing Anbiping at the 122nd position in the industry ranking [1] - Other companies in the industry have significantly lower PE ratios, with the highest being 18.97 for Sanxin Medical [2]

Group 1 - Chengdu High-tech Zone Medical Device Innovation and Transformation Association facilitated Qinglan Jichuang Medical Equipment to obtain a credit line of tens of millions from Chengdu Bank, specifically for production line expansion and technology research and development [1] - Anbiping announced that its HPV nucleic acid test kit received a medical device registration certificate from the National Medical Products Administration, capable of detecting 18 high-risk HPV types and further expanding its layout in the tumor screening field [1] - In the first half of 2025, China approved 45 innovative medical devices, a year-on-year increase of 87%, reflecting the continuous policy dividends driving industry technological upgrades [1] Group 2 - The domestic nuclear medicine industry has a high dependence on imported radionuclide raw materials, but domestic technological breakthroughs and capacity releases are expected to enhance the self-supply capability of major isotopes [2] - The nuclear medicine regulatory environment is strict, creating high barriers to entry, with companies like China Radiopharmaceuticals and Dongcheng Pharmaceutical holding a first-mover advantage in the midstream production and distribution sectors [2] - The nuclear medicine market is projected to grow at a compound annual growth rate of over 20% over the next five years, reaching 26 billion yuan by 2030, driven by policy support and increasing medical resource allocation [2] Group 3 - The ChiNext Medical ETF tracks the Chuangyi Medicine Index, which can experience daily fluctuations of up to 20%, reflecting the overall performance of listed companies in the medical manufacturing, medical devices, and medical services sectors on the ChiNext market [2] - The index consists of companies with innovative characteristics and high growth potential, generally characterized by high research and development investment and industry development potential [2]

Group 1 - The core viewpoint of the news highlights the support for innovation in the medical device industry, with significant funding and regulatory approvals driving growth [1][2] - Chengdu High-tech Zone Medical Device Innovation and Transformation Association assisted a startup in obtaining a credit line in the millions from Chengdu Bank, aimed at expanding production lines and technology research [1] - The National Medical Products Administration (NMPA) reported that 45 innovative medical devices were approved in the first half of 2025, representing a year-on-year increase of 87%, indicating ongoing policy benefits for industry innovation [1] Group 2 - Everbright Securities pointed out that the NMPA's announcement supports the innovation of high-end medical devices, including medical robots, advanced imaging equipment, AI medical devices, and new biomaterials [2] - The document emphasizes the expectation of faster commercialization of innovative medical devices under policy support, with a comprehensive standard system gradually being established for product design, production quality control, and post-market supervision [2] - The document also supports the international development of high-end medical device companies, which is expected to promote standardization and internationalization in the industry, benefiting leading companies with strong R&D capabilities and scalable products [2]

Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index closing at 3493.05, down 0.13%, while the ChiNext Index rose by 0.16% to 2184.67 [2][8] - The total market capitalization of the Shanghai Composite Index is 6782.28 billion, with a price-to-earnings (PE) ratio of 12.48 and a price-to-book (PB) ratio of 1.30 [3] Economic Indicators - In June, China's Producer Price Index (PPI) decreased by 3.6% year-on-year, while the Consumer Price Index (CPI) increased by 0.1%, marking a turnaround after four months of decline [15][17] - The People's Bank of China conducted a 755 billion yuan reverse repurchase operation, indicating ongoing liquidity management [19][20] Industry Dynamics - The renewable energy sector is set to see increased green electricity consumption requirements, with new mandates for industries such as steel and cement [24] - Global lithium battery anode material production reached 1.3025 million tons in the first half of 2025, reflecting a year-on-year growth of 34.7% [26] Company Updates - Zoli Pharmaceutical (300181.SZ) expects a net profit of 368 million to 388 million yuan for the first half of 2025, representing a growth of 24.3% to 31.1% year-on-year [30][31] - Anbiping (688393.SH) received a medical device registration certificate for its HPV nucleic acid test kit, enhancing its strategic position in cancer screening [33][34] - Yunnan Rural Commercial Bank (601077.SH) has obtained approval for securities investment fund custody, marking a significant expansion of its service capabilities [35][36] Sector Insights - The electricity sector is experiencing record-high demand due to ongoing heatwaves, with the maximum power load reaching 1.465 billion kilowatts, a significant increase from previous years [55][56] - Investment opportunities in the electricity sector are highlighted, particularly in thermal and hydropower companies, as demand continues to rise amid high temperatures [58]

Group 1: Company Performance - Northern Rare Earth expects a net profit of 900 million to 960 million yuan for the first half of 2025, representing a year-on-year increase of 1882.54% to 2014.71% [1] - Muyuan Foods anticipates a net profit of 10.5 billion to 11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 924.6% to 973.39% [2] - Hongta Securities projects a net profit of 651 million to 696 million yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [3] Group 2: Business Developments - Dazhihui clarifies that it has not engaged in businesses related to "stablecoins," "virtual asset trading," or "cross-border payments," following a significant stock price fluctuation [4] - Bluetech announces a share transfer agreement where its actual controller will change, with the Ma'anshan Municipal Government becoming the actual controller after the transfer of 18% of shares [5] Group 3: Industry Trends - Jiangsu Electric Power reports a 5.01% year-on-year increase in electricity generation for the first half of 2025 [6] - Jin'an Guoji anticipates a non-recurring net profit growth of 4700% to 6300% for the first half of 2025 [6] - New Beiyang expects a non-recurring net profit growth of 650% to 720% for the first half of 2025 [6]

广州安必平医药科技股份有限公司 关于自愿披露人乳头瘤病毒核酸检测试剂盒（实时荧 光 PCR 法）取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州安必平医药科技股份有限公司(以下简称"公司")近日收到由国家药品 监督管理局颁发的《医疗器械注册证（体外诊断试剂）》，相关信息如下： | 序号 | 产品名称 | 注册证编号 | 注册证有 效期 | 注册 分类 | 适用范围 该产品用于体外定性检 测女性宫颈样本（宫颈 | | --- | --- | --- | --- | --- | --- | | 1 | 人乳头瘤病毒核酸检 测试剂盒（实时荧光 | 国械注准 | 2025.07 至 | Ⅲ | 脱落细胞）中的 18 种中 高危型人乳头瘤病毒 （HPV）DNA，包括：16、 18、26、31、33、35、 | | | PCR 法） | 20253401310 | 2030.07 | | 39、45、51、52、53、 | | | | | | | 56、58、59、66、68、 | | | | | | | ...

Core Viewpoint - Anbiping has received the Medical Device Registration Certificate for its HPV nucleic acid detection kit, which enhances its product offerings in the cervical cancer detection market [1] Group 1: Product Development - The HPV nucleic acid detection kit utilizes real-time fluorescence PCR method for qualitative detection of 18 high-risk HPV DNA types in cervical samples [1] - The product also includes subtype detection for HPV16 and HPV18, which are significant in cervical cancer diagnosis [1] Group 2: Market Expansion - The new product complements the existing HPV detection products of the company, thereby broadening its market presence in cervical cancer screening [1] - The acquisition of the registration certificate supports the company's strategic layout in the tumor screening and diagnosis sector [1]

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - As of July 8, Anbiping's closing price was 29.01 yuan, with a PE ratio of 1213.14, and a total market capitalization of 2.714 billion yuan [1] - The average PE ratio for the medical device industry is 51.58, with a median of 37.46, placing Anbiping at the 122nd position among its industry peers [1][2] Group 2 - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49% [1] - The gross profit margin for Anbiping stands at 61.97% [1]

证券代码：688393 证券简称：安必平 公告编号：2025-030 广州安必平医药科技股份有限公司 关于自愿披露公司及子公司 2025 年 4-6 月获得 资质情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州安必平医药科技股份有限公司(以下简称"公司")及子公司在 2025 年 4-6 月获得国内医疗器械注册/备案证 3 项，获得知识产权类资质 5 项，获得境 外认证 14 项。相关信息如下： 一、获得资质的具体情况 （一） 获得国内医疗器械注册/备案证情况 | 序号 | 产品名称 | 证书编号 | 证书有效期 | 注册 分类 | 所属技 术平台 | | --- | --- | --- | --- | --- | --- | | 1 | 全自动免疫组化染色机 | 粤穗械备 20250188 | 2025.5-长期 | Ⅰ | IHC | | 2 | 全自动免疫组化染色机 | 粤穗械备 20250261 | 2025.6-长期 | Ⅰ | IHC | | | | 粤械注准 | 2025.6- | | | | ...